Kairos Pharma (KAPA) stock soared on Tuesday after the clinical-stage biopharmaceutical company announced results from a Phase 2 clinical trial of ENV-105. This is a candidate in development to treat patients with metastatic castration-resistant prostate cancer (mCRPC).
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Interim results from the study showed positive outcomes, with ENV-105 being well tolerated when combined with standard-of-care practices. As a result, there have been no dose-limiting toxicities or unexpected adverse events reported during the trial.
Kairos Pharma CEO John Yu said, “The favorable safety profile observed in this Phase 2 study is encouraging, as it validates our belief in ENV-105’s clinical potential and supports continued development in a patient population with limited effective treatment options.”
Kairos Pharma Stock Movement Today
Kairos Pharma stock was up 167.11% in pre-market trading on Tuesday, following a 3.51% drop yesterday. The shares were also down 54.93% year-to-date and 72.16% over the past 12 months. With this came heavy trading, as some 101 million shares changed hands, compared to a three-month daily average of about 1.64 million units.
